CIK 0001652935 · <br>Emerging growth company
ACTUATE THERAPEUTICS, INC.
Sign in to watch- Ticker
- ACTU
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473044785
- Phone
- 847-986-4190
- Business address
- 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107
- Open-market buys, last 90 days
- $50,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$50,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-14 | Bios Equity COF, LP Director | Conversion | +573,394 | 573,394 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Option exercise | +8,068 | $5.27 | $43K | 305,457 |
| 2024-08-14 | Bios Equity COF, LP Director | Sale | −5,314 | $9.00 | $48K | 300,143 |
| 2024-08-14 | Bios Equity COF, LP Director | Option exercise | +26,355 | $5.27 | $139K | 997,794 |
| 2024-08-14 | Bios Equity COF, LP Director | Sale | −17,361 | $9.00 | $156K | 980,433 |
| 2024-08-14 | Bios Equity COF, LP Director | Option exercise | +3,528 | $5.27 | $19K | 133,572 |
| 2024-08-14 | Bios Equity COF, LP Director | Sale | −2,324 | $9.00 | $21K | 131,248 |
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Convertible Note | −884,427 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series A Redeemable Convertible Preferred Stock | −525,797 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series A Redeemable Convertible Preferred Stock | −307,538 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-1 Redeemable Convertible Preferred Stock | −141,457 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-1 Redeemable Convertible Preferred Stock | −462,073 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-1 Redeemable Convertible Preferred Stock | −61,857 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-1 Redeemable Convertible Preferred Stock | −153,702 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-2 Redeemable Convertible Preferred Stock | −54,032 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-2 Redeemable Convertible Preferred Stock | −176,499 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-2 Redeemable Convertible Preferred Stock | −23,628 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-2 Redeemable Convertible Preferred Stock | −147,047 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-3 Redeemable Convertible Preferred Stock | −101,900 | 0 | ||
| 2024-08-14 | Bios Equity COF, LP Director | Conversion · Series B-3 Redeemable Convertible Preferred Stock | −332,867 | 0 |
Page 7 of 14 · 272 trades